Cancer Immunology Reserch

Cancer Immunol Res. 2025 Jan 29. doi: 10.1158/2326-6066.CIR-23-0903. Online ahead of print. ABSTRACT Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumour effect of JS-201 combined with radiotherapy and the effect on radiation-induced lung injury (RILI). Different … Read more

Cancer Immunol Res. 2025 Jan 24. doi: 10.1158/2326-6066.CIR-24-0649. Online ahead of print. ABSTRACT Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on UC samples … Read more

Cancer Immunol Res. 2025 Jan 16. doi: 10.1158/2326-6066.CIR-24-0259. Online ahead of print. ABSTRACT Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that employs a guide … Read more

Cancer Immunol Res. 2025 Jan 14. doi: 10.1158/2326-6066.CIR-23-0999. Online ahead of print. ABSTRACT Based on the notion that hypomorphic germline genetic variants are linked to autoimmune diseases, we reasoned that novel targets for cancer immunotherapy might be identified through germline variants associated with greater T-cell infiltration into tumors. Here, we report that while investigating germline … Read more

Cancer Immunol Res. 2025 Jan 13. doi: 10.1158/2326-6066.CIR-24-1003. Online ahead of print. ABSTRACT Tumor-specific HLA class I expression is required for cytotoxic T-cell elimination of cancer cells expressing tumor-associated or neo-antigens. Cancers downregulate antigen presentation to avoid adaptive immunity. The highly polymorphic nature of the genes encoding these proteins, coupled with quaternary-structure changes after formalin … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-24-0857. Online ahead of print. ABSTRACT T cell-based therapies, including Tumor Infiltrating Lymphocyte Therapy (TIL), T cell receptor engineered T cells (TCR T), and Chimeric Antigen Receptor T cells (CAR T), are powerful therapeutic approaches for cancer treatment. While these therapies are primarily known for their direct cytotoxic … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-23-0563. Online ahead of print. ABSTRACT The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers predict the immune landscape in gastric adenocarcinoma-an aggressive cancer often linked to … Read more

Cancer Immunol Res. 2025 Jan 9:OF1-OF19. doi: 10.1158/2326-6066.CIR-23-1011. Online ahead of print. ABSTRACT Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model … Read more

Cancer Immunol Res. 2025 Jan 9;13(1):7. doi: 10.1158/2326-6066.CIR-13-1-WWR. NO ABSTRACT PMID:39780660 | DOI:10.1158/2326-6066.CIR-13-1-WWR

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0775. Online ahead of print. ABSTRACT Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 … Read more